We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Human Genome Sciences Awarded Two-Phase Contract to Supply ABthrax™
News

Human Genome Sciences Awarded Two-Phase Contract to Supply ABthrax™

Human Genome Sciences Awarded Two-Phase Contract to Supply ABthrax™
News

Human Genome Sciences Awarded Two-Phase Contract to Supply ABthrax™

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Human Genome Sciences Awarded Two-Phase Contract to Supply ABthrax™"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Human Genome Sciences, Inc. has announced that it has been awarded a two-phase contract to supply ABthrax™, a human monoclonal antibody developed for use in the treatment of anthrax disease, to the U.S. Government.

Under the first phase of the contract, Human Genome Sciences will supply ten grams of ABthrax to the U.S. Department of Health and Human Services (HHS) for comparative in vitro and in vivo testing.

Under the second phase of the contract, the U. S. Government has the option to place an order within one year for up to 100,000 doses of ABthrax for the Strategic National Stockpile, for use in the treatment of anthrax disease.

The HHS comparative testing results, along with Human Genome Sciences' own preclinical and clinical study results, will form the basis of the U.S. Government's decision process for exercising its option for additional product for the Strategic National Stockpile.

Under terms of the contract (Contract Number HHSO10020050006C), Human Genome Sciences within two months will supply ten grams of ABthrax (raxibacumab) manufactured under cGMP conditions for use in comparative testing to be conducted by HHS.

Human Genome Sciences also will provide support necessary to aid HHS in conducting its independent testing.

Human Genome Sciences is entitled to receive approximately $1.8 million for the first phase of the contract.

The second phase of the contract would be awarded by HHS under the Project BioShield Act of 2004, which is designed to accelerate the development, purchase and availability of medical countermeasures for the Strategic National Stockpile.

James H. Davis, Ph.D., J.D., Executive Vice President and General Counsel of Human Genome Sciences, said, “We are pleased that the U.S. Government has chosen to award this contract to Human Genome Sciences.”

“We are ready to supply the initial quantity of material. We are hopeful that the Government can quickly complete the testing phase, so that we can supply ABthrax to the national stockpile for use in the event of a bioterrorist attack.”

H. Thomas Watkins, Chief Executive Officer, said, “I am very proud of our Human Genome Sciences research and development team for their excellent work in bringing ABthrax to this point without government funds.”

“We hope that our country never faces the need to use this product, but would be grateful for the opportunity to make ABthrax available for the treatment of our citizens and first-responders in case the need should ever arise.”

“We have the manufacturing, R&D and other resources needed to fulfill both the first and second phases of the contract announced today.”

“We are fully prepared to move forward rapidly, once the U.S. Government completes its laboratory testing and places an order for therapeutic doses in quantity.”

Advertisement